Early Versus Delayed Treatment With Laquinimod Demonstrated Significant Reduction In Risk Of Disability Progression – Results Of Three-Year ALLEGRO Study In Relapsing-Remitting Multiple Sclerosis
Results of both studies will be shared with the scientific community following a full analysis of the data.
ABOUT THE STUDIES
Additional detail can be found on the AAN website: http://www.abstracts2view.com/aan/
[S41.004] Comparison of Early and Delayed Oral Laquinimod in Patients with Relapsing-Remitting Multiple Sclerosis: Effects on Disability Progression at 36 Months in the ALLEGRO Trial Giancarlo Comi, Milan, Italy, Douglas Jeffery, Advance, NC, Ludwig Kappos, Basel, Switzerland, Xavier Montalban, Barcelona, Spain, Alexey Boyko, Moscow, Russian Federation, Maria Rocca, Milan, Italy, Massimo Filippi, Milan, Italy[P05.197] Therapeutic Laquinimod Treatment Restores Axon Myelination, Callosal Conduction and Motor Deficit in a Chronic Mouse Model of Multiple Sclerosis Spencer Moore, Los Angeles, CA, Gemmy Hannsun, Los Angeles, CA, Jane Yoon, Los Angeles, CA, Rhusheet Patel, Los Angeles, Timothy Yoo, Los Angeles, CA, Anna Khalaj, Los Angeles, CA, Seema Tiwari-Woodruff, Los Angeles, CA ABOUT LAQUINIMOD Laquinimod is an oral, once-daily CNS-active immunomodulator with a novel mechanism of action being developed for the treatment of MS. In animal models laquinimod crosses the blood brain barrier to potentially have a direct effect on resident CNS inflammation and neurodegeneration. The global Phase III clinical development program evaluating oral laquinimod in MS includes two pivotal studies, ALLEGRO and BRAVO. A third Phase III laquinimod trial, CONCERTO, is evaluating two doses of the investigational product (0.6mg and 1.2mg) in approximately 1,800 patients for up to 24 months, after which patients will continue to an active treatment period with laquinimod for additional 24 months The primary outcome measure will be confirmed disability progression as measured by the Expanded Disability Status Scale (EDSS). In addition to the MS clinical studies, laquinimod is currently in clinical development for Crohn's disease and Lupus. ABOUT MULTIPLE SCLEROSIS MS is the leading cause of neurological disability in young adults. It is estimated that more than 400,000 people in the United States are affected by the disease and that two million people may be affected worldwide. Multiple sclerosis is a degenerative disease of the central nervous system in which inflammation and axonal damage and loss result in the development of progressive disability.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts